川宁生物(301301) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit attributable to shareholders of approximately 136,000 to 145,000 million yuan for 2024, representing a year-on-year increase of 44.59%[5] - The net profit after deducting non-recurring gains and losses is also projected to be between 136,000 and 145,000 million yuan, reflecting a growth of 45.31% compared to the previous year[5] - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm[11] - The performance forecast period is from January 1, 2024, to December 31, 2024[3] - The board of directors has provided a statement regarding the 2024 performance forecast[12] Factors Influencing Profit - The increase in profit is primarily driven by higher sales and prices of cephalosporin products in 2024[7] - The company has improved its production technology, effectively reducing production costs, which contributed to the increase in net profit[8] - The scale of interest-bearing liabilities has decreased, leading to a reduction in interest expenses compared to the previous year[10] Regulatory Compliance and Disclosure - The company will adhere to relevant laws and regulations for timely information disclosure, urging investors to make cautious decisions[11] - The company emphasizes that the specific financial data for 2024 will be disclosed in the official annual report[11]